ID   NK-92.26.5
AC   CVCL_VN57
SY   NK-92fc
DR   Wikidata; Q98127909
RX   PubMed=18424763;
RX   PubMed=22023526;
CC   Population: Caucasian.
CC   Transfected with: HGNC; 3619; FCGR3A.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: Natural killer cell; CL=CL_0000623.
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2142 ! NK-92
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 05-10-23; Version: 6
//
RX   PubMed=18424763; DOI=10.4049/jimmunol.180.9.6392;
RA   Binyamin L., Alpaugh R.K., Hughes T.L., Lutz C.T., Campbell K.S.,
RA   Weiner L.M.;
RT   "Blocking NK cell inhibitory self-recognition promotes
RT   antibody-dependent cellular cytotoxicity in a model of anti-lymphoma
RT   therapy.";
RL   J. Immunol. 180:6392-6401(2008).
//
RX   PubMed=22023526; DOI=10.3109/10428194.2011.634048;
RA   Boissel L., Betancur M., Lu W.-Q., Wels W.S., Marino T., Van Etten R.A.,
RA   Klingemann H.-G.;
RT   "Comparison of mRNA and lentiviral based transfection of natural
RT   killer cells with chimeric antigen receptors recognizing lymphoid
RT   antigens.";
RL   Leuk. Lymphoma 53:958-965(2012).
//